Developer docs
API playgroundTry for free, no card

Search company profiles

SAJA Pharmaceuticals

Full company profile

uuid003cehy

Namestring
SAJA Pharmaceuticals
Legal namestring
SAJA Pharmaceuticals Company
Websiteurl
sajapharma.com
Company typeenum
Private
Founded yearint
1996
Descriptiontext

SAJA Pharmaceuticals is a Saudi Arabian pharmaceutical manufacturer and regional commercializer headquartered in Jeddah, founded in 1996 as a joint venture between Tamer Group (Saudi Arabia) and the Japanese pharmaceutical majors Astellas Pharma and Daiichi Sankyo. The company manufactures solid dosage forms (tablets, capsules) at a 32,000 sq.m. cGMP-compliant plant in Jeddah, supported by automated visual inspection, serialization and aggregation packaging lines, and a computerized Quality Management System; an additional plant operates in 6th of October City, Egypt (acquired in 2017). Its diversified portfolio spans urology (where it holds GCC market leadership), cardiovascular, diabetes, oncology/specialty, primary care, and nutraceuticals, combining SAJA-developed branded generics with licensed products from global partners including Novartis, Sanofi, Xellia, and Synthon.

SAJA generates revenue through three channels: direct sales of its own branded generics, royalty- and license-based commercialization of partner products across the MENA region, and contract manufacturing / secondary packaging services for international partners. It reaches healthcare providers, hospitals, and pharmacies across 12+ MENA countries (Saudi Arabia, Egypt, UAE, Kuwait, Bahrain, Oman, Jordan, Lebanon, Libya, Sudan, Yemen, Iraq) using a hybrid go-to-market of direct field sales plus a network of in-country agents and distributors, supplemented by medical-association partnerships (e.g., Arab Association of Urology), medical education programs, and university collaborations (Curtin University Dubai). The company has sustained double-digit growth over the last five years and is ranked among the top 25 pharmaceutical companies in the GCC, positioning it as a mid-tier regional manufacturer increasingly aligned with Saudi Vision 2030 localization objectives.

Short descriptiontext

SAJA Pharmaceuticals is a Saudi-based JV between Tamer Group, Astellas, and Daiichi Sankyo that manufactures and distributes branded generic and licensed pharmaceuticals across urology, cardiovascular, diabetes, oncology, primary care, and nutraceuticals throughout the MENA region.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersJeddah, Saudi Arabia
HQ citystring
Jeddah
HQ countrystring
Saudi Arabia
HQ regionstring
Middle East
Markets served

Serves global market

Offices15 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
branded generic pharmaceuticals, pharmaceutical manufacturing, licensing and co-commercialization, urology therapeutics, MENA pharmaceutical distribution
Industry5 codes
PRIMARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Manufacturing
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

SAJA generates revenue through the sale of its diversified portfolio covering urology, cardiovascular, diabetes, oncology, specialty care, primary care, and nutraceuticals. The portfolio includes branded generics, partner products, second brands, and licensed products sold across the MENA region.

sajapharma.com
2Licensed and Distributed Products
TypeLicensing Royalties
Description

Revenue from licensed products from international partners (Astellas, Daiichi Sankyo, Novartis, Sanofi, Synthon, Xellia) commercialized in the MENA region, including technology transfer and co-development arrangements.

sajapharma.com
3Contract Manufacturing / Secondary Packaging
TypeProfessional Services
Description

SAJA provides secondary packaging services at its manufacturing facility, reflecting trust in the high quality of SAJA's facilities from international partners, generating revenue from toll manufacturing arrangements.

sajapharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Prescription pharmaceutical products across therapeutic categories
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed; products distributed through pharmacies and healthcare providers across MENA region under prescription.

sajapharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SAJA Pharmaceuticals manufactures and distributes a diversified portfolio of branded generic and licensed pharmaceutical products in solid dosage forms (tablets, capsules, transdermal patches) across urology, cardiovascular, diabetes, oncology/specialty, primary care, and nutraceuticals. The company operates cGMP-compliant manufacturing facilities in Saudi Arabia and Egypt, and serves healthcare providers, hospitals, and pharmacies across the MENA region through its own commercial organization and a network of regional agents. It also provides licensing, co-commercialization, and secondary packaging services to international pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • GCC region Market Leader in Urology
+3 more records
Product overview1 text field

SAJA Pharmaceuticals is a regional pharmaceutical company offering a diversified portfolio of branded generic and licensed pharmaceutical products across six therapeutic categories: Urology, Cardiovascular, Diabetes, Specialty, Primary Care, and Nutraceuticals. The company operates as a joint venture between Tamer Industries (Saudi Arabia) and two Japanese pharmaceutical companies (Daiichi Sankyo and Astellas Pharma). SAJA manufactures solid dosage forms (tablets and capsules) at its facility in Jeddah, Saudi Arabia, and distributes products throughout the MENA region. The product portfolio includes established brands across multiple therapy areas, with licensed products from global pharmaceutical partners including Astellas, Daiichi Sankyo, Novartis, Sanofi, Xellia, and Synthon. The company is expanding into specialty/niche areas including critical care, hospital products, and biotechnology-based treatments.

Product and service41 records
1Alamax
CategoryNutraceuticals
Description

Alamax is a film-coated tablet containing Alpha Lipoic Acid 600mg, an antioxidant supplement for oral use, positioned in SAJA's nutraceuticals portfolio.

2Lactoglobin
CategoryNutraceuticals
Description

Lactoglobin is a 100mg Lactoferrin capsule for oral use, a food supplement derived from cow milk, positioned in SAJA's nutraceuticals portfolio.

3Allair 4 & 5 mg
CategoryPrimary Care
Description

Allair is a Montelukast Sodium chewable tablet in 4mg and 5mg strengths for treatment of allergic rhinitis and asthma prevention in children aged 2-14 years.

4Allair 10 mg
CategoryPrimary Care
Description

Allair 10mg is a Montelukast Sodium chewable tablet for treatment of adults and adolescents 15 years and older with allergic conditions and exercise-induced bronchoconstriction.

5D-CURA
CategoryPrimary Care
Description

D-CURA is a Cholecalciferol 25,000 IU ampoule for oral use, a vitamin D3 supplement for prevention and treatment of vitamin D deficiency.

6Itrazol
CategoryPrimary Care
Description

Itrazol is an Itraconazole 100mg capsule for oral use, an antifungal medication for treatment of vulvovaginal candidosis, pityriasis versicolor, dermatophytoses, oral candidosis, fungal keratitis, systemic mycoses, and onychomycosis.

7Levaquin
CategoryPrimary Care
Description

Levaquin is a Levofloxacin 500mg film-coated tablet for treatment of bacterial infections in sinuses, lungs, urinary tract, prostate gland, and skin.

8Moxican
CategoryPrimary Care
Description

Moxican is a Moxifloxacin 400mg film-coated tablet for treatment of bacterial infections including sinus infections, respiratory infections, and pelvic inflammatory disease.

9Pantomax
CategoryPrimary Care
Description

Pantomax is a Pantoprazole 20mg and 40mg tablet for treatment of duodenal ulcers, gastric ulcers, reflux esophagitis, and conditions requiring acid suppression.

10Roxonin
CategoryPrimary Care
Description

Roxonin is a Loxoprofen Sodium 60mg tablet for relief of inflammation and pain in rheumatoid arthritis, osteoarthritis, lower back pain, and post-operative pain.

11Roxonin Tape
CategoryPrimary Care
Description

Roxonin Tape is a Loxoprofen Sodium 50mg and 100mg transdermal patch for relief of acute and chronic inflammation and pain through topical NSAID administration.

12Depojoy
CategoryPrimary Care
Description

Depojoy is a Dapoxetine 30mg and 60mg film-coated tablet for treatment of premature ejaculation in adult men aged 18-64 years.

13Tando
CategoryPrimary Care
Description

Tando is a Tadalafil 5mg and 20mg film-coated tablet for treatment of erectile dysfunction in adult men.

14Levozin
CategoryPrimary Care
Description

Levozin is a Levocetirizine dihydrochloride 5mg film-coated tablet for treatment of allergic rhinitis and urticaria symptoms.

15Olmetec
CategoryCardiovascular
Description

Olmetec is an Olmesartan Medoxomil 20mg and 40mg tablet for treatment of essential hypertension.

16Olmetec Plus
CategoryCardiovascular
Description

Olmetec Plus is a combination tablet of Olmesartan Medoxomil with Hydrochlorothiazide (20mg/12.5mg, 40mg/12.5mg, 40mg/25mg) for treatment of hypertension.

17SEVIKAR
CategoryCardiovascular
Description

SEVIKAR is a combination tablet of Olmesartan Medoxomil and Amlodipine Besilate (20mg/5mg, 20mg/10mg, 40mg/5mg, 40mg/10mg) for treatment of hypertension.

18SEVIKAR HCT
CategoryCardiovascular
Description

SEVIKAR HCT is a triple combination tablet of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in various strengths for treatment of hypertension.

19Arbavasc HCT
CategoryCardiovascular
Description

Arbavasc HCT is a triple combination tablet of Valsartan, Amlodipine, and Hydrochlorothiazide for treatment of hypertension in patients requiring multiple antihypertensive agents.

20Arbaval
CategoryCardiovascular
Description

Arbaval is a Valsartan 40mg, 80mg, 160mg, and 320mg film-coated tablet for treatment of hypertension and heart failure.

21Arbaval Plus
CategoryCardiovascular
Description

Arbaval Plus is a combination tablet of Valsartan with Hydrochlorothiazide (160/12.5mg, 160/25mg, 320/25mg) for treatment of hypertension.

22Ezechol
CategoryCardiovascular
Description

Ezechol is an Ezetimibe 10mg tablet for lowering cholesterol levels by inhibiting intestinal absorption of cholesterol.

23Lixiana
CategoryCardiovascular
Description

Lixiana is an Edoxaban 15mg, 30mg, and 60mg film-coated tablet for prevention of blood clots in atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism.

24Rozavi
CategoryCardiovascular
Description

Rozavi is a Rosuvastatin 10mg and 20mg film-coated tablet for treatment of hypercholesterolemia and cardiovascular risk reduction.

25Simvaten
CategoryCardiovascular
Description

Simvaten is a Simvastatin 10mg, 20mg, and 40mg tablet for treatment of hypercholesterolemia and cardiovascular disease prevention.

26Jalra
CategoryDiabetes
Description

Jalra is a Vildagliptin 50mg tablet for treatment of type 2 diabetes as monotherapy or in combination with other antidiabetic agents.

27Jalra M
CategoryDiabetes
Description

Jalra M is a combination tablet of Vildagliptin and Metformin (50mg/850mg, 50mg/1000mg) for treatment of type 2 diabetes.

28Vivaro
CategoryDiabetes
Description

Vivaro is an Insulin Glargine solution for injection in pre-filled pens for treatment of diabetes mellitus in adults, adolescents, and children 6 years and older.

29Fegona
CategorySpecialty (Multiple Sclerosis)
Description

Fegona is a Fingolimod 0.5mg capsule for treatment of relapsing-remitting multiple sclerosis in adults.

30Envica
CategorySpecialty (Hepatitis B)
Description

Envica is an Entecavir 0.5mg and 1mg tablet for treatment of chronic hepatitis B virus infection in adults.

31XEMETAN
CategorySpecialty (Oncology)
Description

XEMETAN is an Exemestane 25mg sugar-coated tablet for treatment of hormone-dependent breast cancer in postmenopausal women.

32Marlet
CategorySpecialty (Oncology)
Description

Marlet is a Letrozole 2.5mg film-coated tablet for treatment of breast cancer in postmenopausal women.

33Mavec
CategorySpecialty (Oncology)
Description

Mavec is an Imatinib 100mg and 400mg film-coated tablet for treatment of chronic myeloid leukemia, Philadelphia chromosome-positive ALL, GIST, and other malignancies.

34Lidova
CategorySpecialty (Oncology)
Description

Lidova is a Lenalidomide 5mg, 10mg, and 25mg hard capsule for treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma.

35Bonteo
CategorySpecialty (Osteoporosis)
Description

Bonteo is a Teriparatide (rDNA) 20 micrograms/80 microliters solution for injection in pre-filled pen for treatment of osteoporosis.

36Vesicare
CategoryUrology
Description

Vesicare is a Solifenacin Succinate 5mg and 10mg tablet for symptomatic treatment of urge incontinence and overactive bladder syndrome.

37Betmiga
CategoryUrology
Description

Betmiga is a Mirabegron 50mg tablet for treatment of symptoms of overactive bladder including urgency, frequency, and urgency incontinence.

38OMNIC OCAS
CategoryUrology
Description

OMNIC OCAS is a Tamsulosin Hydrochloride 0.4mg prolonged-release tablet for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

39Critical Care Product Line (Xellia)
CategoryCritical Care / Hospital Care
Description

Critical care product line of anti-infective treatments for hospital patients with serious and life-threatening infections, developed in partnership with Xellia Pharmaceuticals.

40Contract Manufacturing (Secondary Packaging Services)
CategoryContract Manufacturing / Technology Transfer
Description

SAJA provides secondary packaging services at its manufacturing facility, including a dedicated secondary packaging localization area to help international partners begin localization, supported by serialization and aggregation for regulatory compliance and supply chain traceability.

41Pharmacovigilance and Drug Safety Services
CategoryPharmacovigilance / Regulatory Services
Description

SAJA operates pharmacovigilance and drug safety services, including an Adverse Event Reporting service, to support regulatory compliance and patient safety across its product portfolio.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

SAJA Pharma signed a Memorandum of Understanding (MOU) with LIFEPharma to form a powerful strategic collaboration combining SAJA's strong commercial presence and diverse portfolio (urology, cardiovascular, diabetes, oncology, specialty care, primary care) with LIFEPharma's robust manufacturing capabilities including a Dubai-based facility and being the only US FDA-approved pharmaceutical manufacturer in the UAE. The partnership aims to strengthen regional pharmaceutical manufacturing and supply chain capabilities and expand access to high-quality affordable treatments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-01
Description

SAJA entered into a partnership with Synthon (global leader in complex generic pharmaceuticals) to commercialize several products in the MENA region. The partnership combines Synthon's high-quality products with SAJA's local industry-leading expertise to accelerate access to high-quality and affordable medicines. This unique partnership advances Synthon's strategy of strengthening commercial presence in the MENA region.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-11-01
Description

SAJA Pharma signed an MoU with Curtin University Dubai (ranked in the top 1% of universities worldwide) to formalize cooperation through training programs, internship and placement for students, and exchange of knowledge and research opportunities. The signing coincided with the 25th jubilee celebration of SAJA Pharma and the centennial celebration of Tamer Group. Mahmoud Ghaly, General Manager – SAJA GCC & Yemen Cluster, stated SAJA aims to enhance knowledge and skills of the medical community.

4Arab Association of Urology (AAU)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-06-01
Description

The Arab Association of Urology (AAU), the largest urological association in the Middle East, signed an MoU with SAJA to promote effective scientific and training programs to improve urology practice through the Arab School of Urology (ASU) education platform. SAJA and AAU pledged to promote public awareness programs for preventable urological health issues including urinary incontinence, overactive bladder (OAB), and benign prostatic hyperplasia (BPH). Dr. Mohammed Khalil, CEO of SAJA, and Dr. Yasser Farahat, Secretary-General of AAU, signed the MoU.

sajapharma.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-10-01
Description

SAJA entered into a strategic collaboration with Xellia Pharmaceuticals to launch its first Critical care brands that serve a wide range of infectious diseases. Xellia is a global specialty pharmaceutical company focused on anti-infective treatments against serious and life-threatening infections. The contract strengthens SAJA's position in regional markets and supports Saudi Vision 2030 for nationalizing the pharmaceutical industry.

6Arab Maternal Fetal Medicine Expert Group
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2020-01-01
Description

SAJA sponsored the 'Pregnancy Management Challenges Webinar' in association with the Arab Maternal Fetal Medicine Expert Group, with attendance of more than 700 physicians from GCC countries and KSA. This partnership supports SAJA's OB-GYN product portfolio.

sajapharma.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2015-12-01
Description

SAJA signed a licensing agreement with Novartis on 15 December 2015 to launch its first diabetes brand (Jalra and Jalra M) as a second brand for Novartis, using the active ingredient vildagliptin (Galvus). The contract also covers secondary packaging of some of Novartis's vital products at SAJA's manufacturing facility, reflecting confidence in SAJA's high-quality facilities.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2015-01-01
Description

SAJA established a diabetes line in partnership with Sanofi in 2015, contributing to expanded diabetes treatment options in the MENA region. This partnership aligns with the high diabetes prevalence in Saudi Arabia (~20.6% of adults).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Tamer Group is the premier Saudi healthcare company and majority shareholder in SAJA Pharmaceuticals. Established in 1922, Tamer Group is a leading supplier of healthcare products in the MENA region with annual turnover exceeding $1.3 billion. SAJA is the manufacturing arm of Tamer Group, producing the latest researched products as well as generics for the MENA region.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Astellas is a global pharmaceutical company with corporate origins in Japan. SAJA is a joint venture between Tamer Industries and Astellas Pharma Inc. Astellas engages in research, development, manufacture, import, and export of pharmaceutical products focusing on therapeutic fields including transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan, present in more than 20 countries with over 100 years of scientific expertise. SAJA is a joint venture between Tamer Industries and Daiichi Sankyo Company Ltd. The partnership provides innovative products and technology transfer for the MENA market.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

India-headquartered global pharmaceutical company with a significant MENA and emerging-markets presence across respiratory, cardiovascular, and oncology. Competes with SAJA on branded generics and licensing-in arrangements across the GCC and broader region.

TypeOthers
Description

Japan-based global pharmaceutical company and JV shareholder of SAJA. Relevant as a key strategic partner and licensor of SAJA's urology and specialty products, shaping SAJA's product portfolio direction.

3Gulf Pharmaceutical Industries (Julphar)
TypeDirect peer
Description

UAE-based pharmaceutical manufacturer with MENA distribution, producing branded generics in diabetes, cardiovascular, and primary care categories. Directly comparable to SAJA as a Gulf-region pharma manufacturer with similar therapeutic breadth and regional MENA commercial reach.

TypeBroad incumbent
Description

India-headquartered global generics manufacturer with active MENA commercial operations, including partnerships for branded generics and biosimilars. Comparable as a global generics player expanding in the same MENA markets where SAJA operates.

TypeDirect peer
Description

Saudi Arabia's largest pharmaceutical manufacturer, listed on Tadawul, producing branded generics across similar therapeutic categories (cardiovascular, diabetes, urology, antibiotics) with direct sales across MENA. Closest direct competitor to SAJA in the Saudi branded-generics space with overlapping product portfolios.

TypeOthers
Description

Global pharmaceutical major and SAJA's diabetes-line licensing partner (since 2015) for vildagliptin-based products in MENA. Comparable as a multinational pharma company that partners with SAJA for regional commercialization rather than competing directly in the same channel.

TypeDirect peer
Description

One of Egypt's largest pharmaceutical manufacturers, producing branded generics across antibiotics, cardiovascular, and diabetes, with exports across MENA and Africa. Comparable to SAJA's Egyptian subsidiary footprint and overlapping regional export markets.

TypeDirect peer
Description

Saudi pharma manufacturer headquartered in Tabuk with a diversified branded-generics portfolio spanning cardiovascular, anti-infectives, CNS, and urology. Competes directly with SAJA for tenders and private-market share in KSA and exports to MENA.

TypeBroad incumbent
Description

MENA-origin global specialty pharmaceutical company headquartered in Jordan, producing branded and injectable generics across MENA, US, and Europe. Broader and larger incumbent than SAJA, with overlapping MENA presence and direct competition in cardiovascular, anti-infectives, and oncology generics.

TypeDirect peer
Description

Saudi Arabia-based pharmaceutical company focused on branded generics in dermatology, pain management, and primary care. Competes with SAJA in the Saudi branded-generics space and shares similar KSA distribution channels and HCP promotional model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SAJA Pharmaceuticals

Pharmaceutical Manufacturingsajapharma.com

SAJA Pharmaceuticals is a Saudi-based JV between Tamer Group, Astellas, and Daiichi Sankyo that manufactures and distributes branded generic and licensed pharmaceuticals across urology, cardiovascular, diabetes, oncology, primary care, and nutraceuticals throughout the MENA region.

What SAJA Pharmaceuticals does

SAJA Pharmaceuticals is a Saudi Arabian pharmaceutical manufacturer and regional commercializer headquartered in Jeddah, founded in 1996 as a joint venture between Tamer Group (Saudi Arabia) and the Japanese pharmaceutical majors Astellas Pharma and Daiichi Sankyo. The company manufactures solid dosage forms (tablets, capsules) at a 32,000 sq.m. cGMP-compliant plant in Jeddah, supported by automated visual inspection, serialization and aggregation packaging lines, and a computerized Quality Management System; an additional plant operates in 6th of October City, Egypt (acquired in 2017). Its diversified portfolio spans urology (where it holds GCC market leadership), cardiovascular, diabetes, oncology/specialty, primary care, and nutraceuticals, combining SAJA-developed branded generics with licensed products from global partners including Novartis, Sanofi, Xellia, and Synthon.

SAJA generates revenue through three channels: direct sales of its own branded generics, royalty- and license-based commercialization of partner products across the MENA region, and contract manufacturing / secondary packaging services for international partners. It reaches healthcare providers, hospitals, and pharmacies across 12+ MENA countries (Saudi Arabia, Egypt, UAE, Kuwait, Bahrain, Oman, Jordan, Lebanon, Libya, Sudan, Yemen, Iraq) using a hybrid go-to-market of direct field sales plus a network of in-country agents and distributors, supplemented by medical-association partnerships (e.g., Arab Association of Urology), medical education programs, and university collaborations (Curtin University Dubai). The company has sustained double-digit growth over the last five years and is ranked among the top 25 pharmaceutical companies in the GCC, positioning it as a mid-tier regional manufacturer increasingly aligned with Saudi Vision 2030 localization objectives.

SAJA Pharmaceuticals firmographics

Firmographics
Name
SAJA Pharmaceuticals
Legal name
SAJA Pharmaceuticals Company
Website
https://sajapharma.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
11–50 employees
Short description
SAJA Pharmaceuticals is a Saudi-based JV between Tamer Group, Astellas, and Daiichi Sankyo that manufactures and distributes branded generic and licensed pharmaceuticals across urology, cardiovascular, diabetes, oncology, primary care, and nutraceuticals throughout the MENA region.
Ownership category
akta.pro rank

SAJA Pharmaceuticals industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Branded generic pharmaceuticals
  • Pharmaceutical manufacturing
  • Licensing and co-commercialization
  • Urology therapeutics
  • MENA pharmaceutical distribution

Where SAJA Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Jeddah
HQ country
Saudi Arabia
HQ region
Middle East

Offices15 records

Markets served

SAJA Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: SAJA generates revenue through the sale of its diversified portfolio covering urology, cardiovascular, diabetes, oncology, specialty care, primary care, and nutraceuticals. The portfolio includes branded generics, partner products, second brands, and licensed products sold across the MENA region.
  2. Licensed and Distributed Products: Revenue from licensed products from international partners (Astellas, Daiichi Sankyo, Novartis, Sanofi, Synthon, Xellia) commercialized in the MENA region, including technology transfer and co-development arrangements.
  3. Contract Manufacturing / Secondary Packaging: SAJA provides secondary packaging services at its manufacturing facility, reflecting trust in the high quality of SAJA's facilities from international partners, generating revenue from toll manufacturing arrangements.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPrescription pharmaceutical products across therapeutic categories

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

SAJA Pharmaceuticals product offering

Product offering

Core offering

SAJA Pharmaceuticals manufactures and distributes a diversified portfolio of branded generic and licensed pharmaceutical products in solid dosage forms (tablets, capsules, transdermal patches) across urology, cardiovascular, diabetes, oncology/specialty, primary care, and nutraceuticals. The company operates cGMP-compliant manufacturing facilities in Saudi Arabia and Egypt, and serves healthcare providers, hospitals, and pharmacies across the MENA region through its own commercial organization and a network of regional agents. It also provides licensing, co-commercialization, and secondary packaging services to international pharmaceutical partners.

Product overview

SAJA Pharmaceuticals is a regional pharmaceutical company offering a diversified portfolio of branded generic and licensed pharmaceutical products across six therapeutic categories: Urology, Cardiovascular, Diabetes, Specialty, Primary Care, and Nutraceuticals. The company operates as a joint venture between Tamer Industries (Saudi Arabia) and two Japanese pharmaceutical companies (Daiichi Sankyo and Astellas Pharma). SAJA manufactures solid dosage forms (tablets and capsules) at its facility in Jeddah, Saudi Arabia, and distributes products throughout the MENA region. The product portfolio includes established brands across multiple therapy areas, with licensed products from global pharmaceutical partners including Astellas, Daiichi Sankyo, Novartis, Sanofi, Xellia, and Synthon. The company is expanding into specialty/niche areas including critical care, hospital products, and biotechnology-based treatments.

Differentiator

Problem solved

Functional benefit

Products and services

  • Alamax Alamax is a film-coated tablet containing Alpha Lipoic Acid 600mg, an antioxidant supplement for oral use, positioned in SAJA's nutraceuticals portfolio.
  • Lactoglobin Lactoglobin is a 100mg Lactoferrin capsule for oral use, a food supplement derived from cow milk, positioned in SAJA's nutraceuticals portfolio.
  • Allair 4 & 5 mg Allair is a Montelukast Sodium chewable tablet in 4mg and 5mg strengths for treatment of allergic rhinitis and asthma prevention in children aged 2-14 years.
  • Allair 10 mg Allair 10mg is a Montelukast Sodium chewable tablet for treatment of adults and adolescents 15 years and older with allergic conditions and exercise-induced bronchoconstriction.
  • D-CURA D-CURA is a Cholecalciferol 25,000 IU ampoule for oral use, a vitamin D3 supplement for prevention and treatment of vitamin D deficiency.
  • Itrazol Itrazol is an Itraconazole 100mg capsule for oral use, an antifungal medication for treatment of vulvovaginal candidosis, pityriasis versicolor, dermatophytoses, oral candidosis, fungal keratitis, systemic mycoses, and onychomycosis.
  • Levaquin Levaquin is a Levofloxacin 500mg film-coated tablet for treatment of bacterial infections in sinuses, lungs, urinary tract, prostate gland, and skin.
  • Moxican Moxican is a Moxifloxacin 400mg film-coated tablet for treatment of bacterial infections including sinus infections, respiratory infections, and pelvic inflammatory disease.
  • Pantomax Pantomax is a Pantoprazole 20mg and 40mg tablet for treatment of duodenal ulcers, gastric ulcers, reflux esophagitis, and conditions requiring acid suppression.
  • Roxonin Roxonin is a Loxoprofen Sodium 60mg tablet for relief of inflammation and pain in rheumatoid arthritis, osteoarthritis, lower back pain, and post-operative pain.
  • Roxonin Tape Roxonin Tape is a Loxoprofen Sodium 50mg and 100mg transdermal patch for relief of acute and chronic inflammation and pain through topical NSAID administration.
  • Depojoy Depojoy is a Dapoxetine 30mg and 60mg film-coated tablet for treatment of premature ejaculation in adult men aged 18-64 years.
  • Tando Tando is a Tadalafil 5mg and 20mg film-coated tablet for treatment of erectile dysfunction in adult men.
  • Levozin Levozin is a Levocetirizine dihydrochloride 5mg film-coated tablet for treatment of allergic rhinitis and urticaria symptoms.
  • Olmetec Olmetec is an Olmesartan Medoxomil 20mg and 40mg tablet for treatment of essential hypertension.
  • Olmetec Plus Olmetec Plus is a combination tablet of Olmesartan Medoxomil with Hydrochlorothiazide (20mg/12.5mg, 40mg/12.5mg, 40mg/25mg) for treatment of hypertension.
  • SEVIKAR SEVIKAR is a combination tablet of Olmesartan Medoxomil and Amlodipine Besilate (20mg/5mg, 20mg/10mg, 40mg/5mg, 40mg/10mg) for treatment of hypertension.
  • SEVIKAR HCT SEVIKAR HCT is a triple combination tablet of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in various strengths for treatment of hypertension.
  • Arbavasc HCT Arbavasc HCT is a triple combination tablet of Valsartan, Amlodipine, and Hydrochlorothiazide for treatment of hypertension in patients requiring multiple antihypertensive agents.
  • Arbaval Arbaval is a Valsartan 40mg, 80mg, 160mg, and 320mg film-coated tablet for treatment of hypertension and heart failure.
  • Arbaval Plus Arbaval Plus is a combination tablet of Valsartan with Hydrochlorothiazide (160/12.5mg, 160/25mg, 320/25mg) for treatment of hypertension.
  • Ezechol Ezechol is an Ezetimibe 10mg tablet for lowering cholesterol levels by inhibiting intestinal absorption of cholesterol.
  • Lixiana Lixiana is an Edoxaban 15mg, 30mg, and 60mg film-coated tablet for prevention of blood clots in atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism.
  • Rozavi Rozavi is a Rosuvastatin 10mg and 20mg film-coated tablet for treatment of hypercholesterolemia and cardiovascular risk reduction.
  • Simvaten Simvaten is a Simvastatin 10mg, 20mg, and 40mg tablet for treatment of hypercholesterolemia and cardiovascular disease prevention.
  • Jalra Jalra is a Vildagliptin 50mg tablet for treatment of type 2 diabetes as monotherapy or in combination with other antidiabetic agents.
  • Jalra M Jalra M is a combination tablet of Vildagliptin and Metformin (50mg/850mg, 50mg/1000mg) for treatment of type 2 diabetes.
  • Vivaro Vivaro is an Insulin Glargine solution for injection in pre-filled pens for treatment of diabetes mellitus in adults, adolescents, and children 6 years and older.
  • Fegona Fegona is a Fingolimod 0.5mg capsule for treatment of relapsing-remitting multiple sclerosis in adults.
  • Envica Envica is an Entecavir 0.5mg and 1mg tablet for treatment of chronic hepatitis B virus infection in adults.
  • XEMETAN XEMETAN is an Exemestane 25mg sugar-coated tablet for treatment of hormone-dependent breast cancer in postmenopausal women.
  • Marlet Marlet is a Letrozole 2.5mg film-coated tablet for treatment of breast cancer in postmenopausal women.
  • Mavec Mavec is an Imatinib 100mg and 400mg film-coated tablet for treatment of chronic myeloid leukemia, Philadelphia chromosome-positive ALL, GIST, and other malignancies.
  • Lidova Lidova is a Lenalidomide 5mg, 10mg, and 25mg hard capsule for treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma.
  • Bonteo Bonteo is a Teriparatide (rDNA) 20 micrograms/80 microliters solution for injection in pre-filled pen for treatment of osteoporosis.
  • Vesicare Vesicare is a Solifenacin Succinate 5mg and 10mg tablet for symptomatic treatment of urge incontinence and overactive bladder syndrome.
  • Betmiga Betmiga is a Mirabegron 50mg tablet for treatment of symptoms of overactive bladder including urgency, frequency, and urgency incontinence.
  • OMNIC OCAS OMNIC OCAS is a Tamsulosin Hydrochloride 0.4mg prolonged-release tablet for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
  • Critical Care Product Line (Xellia) Critical care product line of anti-infective treatments for hospital patients with serious and life-threatening infections, developed in partnership with Xellia Pharmaceuticals.
  • Contract Manufacturing (Secondary Packaging Services) SAJA provides secondary packaging services at its manufacturing facility, including a dedicated secondary packaging localization area to help international partners begin localization, supported by serialization and aggregation for regulatory compliance and supply chain traceability.
  • Pharmacovigilance and Drug Safety Services SAJA operates pharmacovigilance and drug safety services, including an Adverse Event Reporting service, to support regulatory compliance and patient safety across its product portfolio.

Quantifiable outcome

  • GCC region Market Leader in Urology
  • +3 more outcomes

Companies that use SAJA Pharmaceuticals

Customer profile

Named customers1 record

Segments7 records

Ideal customer profiles3 records

SAJA Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

SAJA Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

  • LIFEPharmacoreStrategic or Co-development Partner · 1 January 2025SAJA Pharma signed a Memorandum of Understanding (MOU) with LIFEPharma to form a powerful strategic collaboration combining SAJA's strong commercial presence and diverse portfolio (urology, cardiovascular, diabetes, oncology, specialty care, primary care) with LIFEPharma's robust manufacturing capabilities including a Dubai-based facility and being the only US FDA-approved pharmaceutical manufacturer in the UAE. The partnership aims to strengthen regional pharmaceutical manufacturing and supply chain capabilities and expand access to high-quality affordable treatments.
  • SynthoncoreStrategic or Co-development Partner · 1 December 2022SAJA entered into a partnership with Synthon (global leader in complex generic pharmaceuticals) to commercialize several products in the MENA region. The partnership combines Synthon's high-quality products with SAJA's local industry-leading expertise to accelerate access to high-quality and affordable medicines. This unique partnership advances Synthon's strategy of strengthening commercial presence in the MENA region.
  • Curtin University DubaimajorStrategic or Co-development Partner · 1 November 2022SAJA Pharma signed an MoU with Curtin University Dubai (ranked in the top 1% of universities worldwide) to formalize cooperation through training programs, internship and placement for students, and exchange of knowledge and research opportunities. The signing coincided with the 25th jubilee celebration of SAJA Pharma and the centennial celebration of Tamer Group. Mahmoud Ghaly, General Manager – SAJA GCC & Yemen Cluster, stated SAJA aims to enhance knowledge and skills of the medical community.
  • Arab Association of Urology (AAU)majorStrategic or Co-development Partner · 1 June 2022The Arab Association of Urology (AAU), the largest urological association in the Middle East, signed an MoU with SAJA to promote effective scientific and training programs to improve urology practice through the Arab School of Urology (ASU) education platform. SAJA and AAU pledged to promote public awareness programs for preventable urological health issues including urinary incontinence, overactive bladder (OAB), and benign prostatic hyperplasia (BPH). Dr. Mohammed Khalil, CEO of SAJA, and Dr. Yasser Farahat, Secretary-General of AAU, signed the MoU.
  • Xellia PharmaceuticalscoreStrategic or Co-development Partner · 1 October 2020SAJA entered into a strategic collaboration with Xellia Pharmaceuticals to launch its first Critical care brands that serve a wide range of infectious diseases. Xellia is a global specialty pharmaceutical company focused on anti-infective treatments against serious and life-threatening infections. The contract strengthens SAJA's position in regional markets and supports Saudi Vision 2030 for nationalizing the pharmaceutical industry.
  • Arab Maternal Fetal Medicine Expert GroupminorGTM or Marketing Partner · 1 January 2020SAJA sponsored the 'Pregnancy Management Challenges Webinar' in association with the Arab Maternal Fetal Medicine Expert Group, with attendance of more than 700 physicians from GCC countries and KSA. This partnership supports SAJA's OB-GYN product portfolio.
  • NovartiscoreOEM/ Whitelabel/ Licensing Partner · 1 December 2015SAJA signed a licensing agreement with Novartis on 15 December 2015 to launch its first diabetes brand (Jalra and Jalra M) as a second brand for Novartis, using the active ingredient vildagliptin (Galvus). The contract also covers secondary packaging of some of Novartis's vital products at SAJA's manufacturing facility, reflecting confidence in SAJA's high-quality facilities.
  • SanoficoreOEM/ Whitelabel/ Licensing Partner · 1 January 2015SAJA established a diabetes line in partnership with Sanofi in 2015, contributing to expanded diabetes treatment options in the MENA region. This partnership aligns with the high diabetes prevalence in Saudi Arabia (~20.6% of adults).
  • Tamer GroupcoreStrategic or Co-development PartnerTamer Group is the premier Saudi healthcare company and majority shareholder in SAJA Pharmaceuticals. Established in 1922, Tamer Group is a leading supplier of healthcare products in the MENA region with annual turnover exceeding $1.3 billion. SAJA is the manufacturing arm of Tamer Group, producing the latest researched products as well as generics for the MENA region.
  • Astellas Pharma Inc.coreStrategic or Co-development PartnerAstellas is a global pharmaceutical company with corporate origins in Japan. SAJA is a joint venture between Tamer Industries and Astellas Pharma Inc. Astellas engages in research, development, manufacture, import, and export of pharmaceutical products focusing on therapeutic fields including transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases.
  • Daiichi Sankyo Company Ltd.coreStrategic or Co-development PartnerDaiichi Sankyo is a global pharmaceutical company with corporate origins in Japan, present in more than 20 countries with over 100 years of scientific expertise. SAJA is a joint venture between Tamer Industries and Daiichi Sankyo Company Ltd. The partnership provides innovative products and technology transfer for the MENA market.

Scale indicators7 records

Recent moves11 records

Expansion highlights6 records

SAJA Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Cipla: India-headquartered global pharmaceutical company with a significant MENA and emerging-markets presence across respiratory, cardiovascular, and oncology. Competes with SAJA on branded generics and licensing-in arrangements across the GCC and broader region.
  • Dr. Reddy's Laboratories: India-headquartered global generics manufacturer with active MENA commercial operations, including partnerships for branded generics and biosimilars. Comparable as a global generics player expanding in the same MENA markets where SAJA operates.
  • Hikma Pharmaceuticals: MENA-origin global specialty pharmaceutical company headquartered in Jordan, producing branded and injectable generics across MENA, US, and Europe. Broader and larger incumbent than SAJA, with overlapping MENA presence and direct competition in cardiovascular, anti-infectives, and oncology generics.

Others

  • Astellas Pharma Inc. Japan-based global pharmaceutical company and JV shareholder of SAJA. Relevant as a key strategic partner and licensor of SAJA's urology and specialty products, shaping SAJA's product portfolio direction.
  • Sanofi: Global pharmaceutical major and SAJA's diabetes-line licensing partner (since 2015) for vildagliptin-based products in MENA. Comparable as a multinational pharma company that partners with SAJA for regional commercialization rather than competing directly in the same channel.

Direct peers

  • Gulf Pharmaceutical Industries (Julphar): UAE-based pharmaceutical manufacturer with MENA distribution, producing branded generics in diabetes, cardiovascular, and primary care categories. Directly comparable to SAJA as a Gulf-region pharma manufacturer with similar therapeutic breadth and regional MENA commercial reach.
  • SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi Arabia's largest pharmaceutical manufacturer, listed on Tadawul, producing branded generics across similar therapeutic categories (cardiovascular, diabetes, urology, antibiotics) with direct sales across MENA. Closest direct competitor to SAJA in the Saudi branded-generics space with overlapping product portfolios.
  • Egyptian International Pharmaceutical Industries Company (EIPICO): One of Egypt's largest pharmaceutical manufacturers, producing branded generics across antibiotics, cardiovascular, and diabetes, with exports across MENA and Africa. Comparable to SAJA's Egyptian subsidiary footprint and overlapping regional export markets.
  • Tabuk Pharmaceuticals Manufacturing Company: Saudi pharma manufacturer headquartered in Tabuk with a diversified branded-generics portfolio spanning cardiovascular, anti-infectives, CNS, and urology. Competes directly with SAJA for tenders and private-market share in KSA and exports to MENA.
  • Avalon Pharma: Saudi Arabia-based pharmaceutical company focused on branded generics in dermatology, pain management, and primary care. Competes with SAJA in the Saudi branded-generics space and shares similar KSA distribution channels and HCP promotional model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

SAJA Pharmaceuticals social profiles

Digital presence

SAJA Pharmaceuticals compliance and trust

Trust signal

Compliance2 records

SAJA Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SAJA Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

SAJA Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

SAJA Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SAJA Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SAJA Pharmaceuticals

What does SAJA Pharmaceuticals do?

SAJA Pharmaceuticals manufactures and distributes a diversified portfolio of branded generic and licensed pharmaceutical products in solid dosage forms (tablets, capsules, transdermal patches) across urology, cardiovascular, diabetes, oncology/specialty, primary care, and nutraceuticals. The company operates cGMP-compliant manufacturing facilities in Saudi Arabia and Egypt, and serves healthcare providers, hospitals, and pharmacies across the MENA region through its own commercial organization and a network of regional agents. It also provides licensing, co-commercialization, and secondary packaging services to international pharmaceutical partners.

Is SAJA Pharmaceuticals a public or private company?

SAJA Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.

When was SAJA Pharmaceuticals founded?

SAJA Pharmaceuticals was founded in 1996. It employs 11 to 50 people.

Where is SAJA Pharmaceuticals based?

SAJA Pharmaceuticals is headquartered in Jeddah, Saudi Arabia, in the Middle East region.

How does SAJA Pharmaceuticals make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensed and Distributed Products and contract Manufacturing / Secondary Packaging.

Who are SAJA Pharmaceuticals's main competitors?

Broad incumbents on record are Cipla, Dr. Reddy's Laboratories and Hikma Pharmaceuticals. Others are Astellas Pharma Inc. and Sanofi. Direct peers are Gulf Pharmaceutical Industries (Julphar), SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation), Egyptian International Pharmaceutical Industries Company (EIPICO), Tabuk Pharmaceuticals Manufacturing Company and Avalon Pharma.

Does SAJA Pharmaceuticals have an API?

No public API is recorded for SAJA Pharmaceuticals.

What industry is SAJA Pharmaceuticals in?

SAJA Pharmaceuticals's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAM, Nephrology & Urology Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals